Form 4 for BEAM Beam Therapeutics Inc.
Accepted 2026-07-01 16:05:11 ET · period of report 2026-06-29 · accession 0001193125-26-292526 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-07-01 16:05 | 2026-06-29+ | BEAM | Evans John M. | CEO, Dir | M - OptEx | $0.8956 | +50.0K | 1.07M | +5% | +$44.8K |
| DMT | 2026-07-01 16:05 | 2026-06-29+ | BEAM | Evans John M. | CEO, Dir | S - Sale+OE | $34.90 | -50.0K | 1.05M | -5% | -$1.75M |
| DMT | 2026-07-01 16:05 | 2026-06-29+ | BEAM | Evans John M. | CEO, Dir | M - OptEx | $0.00 | -50.0K | 205.8K | -20% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-06-29 | M | A | 18,663 | $0.67 | 1,065,868 | D | — | — | (F1) The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. |
| 2 | Common | Common Stock | 2026-06-29 | M | A | 6,337 | $1.03 | 1,072,205 | D | — | — | (F1) The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. |
| 3 | Common | Common Stock | 2026-06-29 | S | D | 13,421 | $35.13 | 1,058,784 | D | — | — | (F1) The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $34.55 to $35.50, inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| 4 | Common | Common Stock | 2026-06-29 | S | D | 11,579 | $35.91 | 1,047,205 | D | — | — | (F1) The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $35.60 to $36.18, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| 5 | Common | Common Stock | 2026-06-30 | M | A | 25,000 | $1.03 | 1,072,205 | D | — | — | (F1) The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. |
| 6 | Common | Common Stock | 2026-06-30 | S | D | 23,100 | $34.26 | 1,049,105 | D | — | — | (F1) The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. (F4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $33.80 to $34.71, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| 7 | Common | Common Stock | 2026-06-30 | S | D | 1,900 | $34.84 | 1,047,205 | D | — | — | (F1) The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. (F5) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $34.83 to $34.85, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| 8 | Derivative | Stock Option (Right to Buy) | 2026-06-29 | M | D | 18,663 | $0.00 | 9 | D | $0.67 · — to 2028-05-08 | 18,663 Common Stock | (F1) The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. (F6) On May 8, 2018, the Reporting Person was granted an option to purchase shares of common stock, which vested as to 99,396 shares upon the achievement of a certain development milestone related to base editing applications. On April 3, 2024, the board of directors of BEAM determined that this performance condition was achieved, resulting in the vesting of 99,336 shares. |
| 9 | Derivative | Stock Option (Right to Buy) | 2026-06-29 | M | D | 6,337 | $0.00 | 230,804 | D | $1.03 · — to 2028-07-13 | 6,337 Common Stock | (F1) The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. (F7) On July 13, 2018, the Reporting Person was granted an option to purchase 539,645 shares of common stock, which vested as to 25% of the underlying shares on January 8, 2019 and in 36 equal monthly installments thereafter. |
| 10 | Derivative | Stock Option (Right to Buy) | 2026-06-30 | M | D | 25,000 | $0.00 | 205,804 | D | $1.03 · — to 2028-07-13 | 25,000 Common Stock | (F1) The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. (F7) On July 13, 2018, the Reporting Person was granted an option to purchase 539,645 shares of common stock, which vested as to 25% of the underlying shares on January 8, 2019 and in 36 equal monthly installments thereafter. |